Alunacedase alfa for COVID-19: real-time analysis

Download Image

Post

c19early.org

Alunacedase alfa for COVID-19

1 study with 178 patients

Serious outcome risk

Alunacedase alfa

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Alunacedase alfa studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−31%

Mortality (1)−31%

RCTs (1)−31%

Late (1)−31%

00.511.5+

← Alunacedase
alfa reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Alunacedase alfa (APN01) is a recombinant soluble ACE2 biologic that acts as a decoy receptor and RAS-modulating enzyme to potentially neutralize SARS-CoV-2 and mitigate COVID-19 lung injury.


Dec 26 2020	Bundgaard et al., NCT04335136	Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
Dec 26 2020	31% higher mortality (p=0.61) and 23% lower ventilation (p=0.64). RCT 181 hospitalized COVID-19 patients showing no significant improvement with alunacedase alfa.